Navigation Links
Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Date:9/28/2011

NEW YORK, Sept. 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0648872/Acute-Ischemic-Stroke-AIS-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory

Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global acute ischemic stroke therapeutics market. The report identifies the key trends shaping and driving the global acute ischemic stroke therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global acute ischemic stroke therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the acute ischemic stroke market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) acute ischemic stroke therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as immunomodulators, NMDA receptor antagonists, platelet inhibitor, polyketide antibiotics, and recombinant proteins amongst others.

- Analysis of the current and future competition in the seven key countries acute ischemic stroke therapeutics market. Key market players covered are Celgene Corporation, Cidat C.V. Corrimum Gmbh, D-Pharm Ltd., H Lundbeck A/S, Mitsubhishi Tanabe Pharma, Panacea Pharmaceuticals, Pfizer, Inc., Sanofi, Stemedica Cell Technologies, Vernalis PLC.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the acute ischemic stroke market.

- Analysis of key recent licensing and partnership agreements in acute ischemic stroke therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global acute ischemic stroke market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global acute ischemic stroke market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global acute ischemic stroke market landscape? – Identify, understand and capitalize.

To order this report:

: Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
5. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
8. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
11. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent ... as the number one company for hearing aids, ranking it ... fifteen other brands. ... Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, ...
(Date:9/7/2017)... 7, 2017  Eli Lilly and Company (NYSE: ... streamline operations to more efficiently focus resources on ... structure. Global workforce reductions, including those from a ... impact approximately 3,500 positions. With ... savings of approximately $500 million that will begin ...
(Date:9/7/2017)... , Sept. 7, 2017   BioLife Solutions , ... and marketer of proprietary clinical grade cell and tissue ... announces that Mike Rice , President and CEO, will ... Rodman & Renshaw 19 th Annual ... Eastern time (12:25 p.m. Pacific time). The conference is being ...
Breaking Medicine Technology:
(Date:9/22/2017)... PITTSBURGH, PA (PRWEB) , ... September 22, 2017 ... ... as soon as possible, and they often saves lives. However, if one isn’t ... order to widen the availability of defibrillation, I came up with this idea," ...
(Date:9/22/2017)... ... 22, 2017 , ... After a long health ordeal that ... lease on life with assistance from CreditAssociates. CreditAssociates provides debt relief and debt ... debt. The senior is one of the satisfied clients who expressed their appreciation ...
(Date:9/22/2017)... ... September 22, 2017 , ... Happy Living’s mission - to improve ... carries it into the entertaining and delicious worlds of theatre and wines. , ... Living) convinced him to turn his play into a book. The Greener The Grass ...
(Date:9/22/2017)... ... September 22, 2017 , ... TopConsumerReviews.com ... by Native Remedies that helps promote pancreatic health and regulate blood sugar ... some prescription-based approaches can have negative side effects, and with the changes in ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... brush more effectively even on the go. Their electric toothbrushes aggressively attack oral ... inflammation, with UV sanitizing technology. Combining leading edge Enke technology with a premium ...
Breaking Medicine News(10 mins):